The U.S. Court of Appeals for the Federal Circuit has rejected a request from Novartis (NVS -0.0%) unit Sandoz to reconsider a July 1 ruling by the original three-judge panel upholding two patents covering Amgen's (AMGN -0.4%) arthritis/psoriasis med Enbrel (etanercept). The company wanted the case to be heard before all 12 active judges.
The ruling prevents Sandoz from selling a biosimilar version branded as Erelzi, approved by the FDA in August 2016.
https://seekingalpha.com/news/3618086-amgen-prevails-in-enbrel-patent-dispute-novartis
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.